Dear HOM3OSTASIS Community,

I’m thrilled to share some important news.

First, let me emphasize: there is already a wealth of medical evidence supporting each of the three CNT nutrients — C (ascorbic acid), N (nicotinic acid), and T (L-tryptophan) — across decades of research. Each has been shown to play critical roles in metabolism, immunity, brain health, and recovery. What makes HOM3OSTASIS unique is that we bring them together in their precise stoichiometric balance, unlocking a synergy that is far greater than any one of them alone.

Now, the Florida Department of Health has just opened applications for the Florida Cancer Innovation Fund (FY 2025–26) — and for the first time ever, they are fast-tracking research that focuses specifically on new nutrition-based cancer prevention regimens. This is exactly the kind of opening we’ve been waiting for.

👉 Official FOA: Florida Cancer Innovation Fund 2025–26

In parallel, we are also closely watching the Ed & Ethel Moore Alzheimer’s Disease Research Program, which will release its new FOA soon for FY 2025–26. This program previously emphasized multivitamin strategies for cognitive decline, and it’s a natural fit for our work as well.

👉 Current FOA page: Florida Alzheimer’s Research Funding

How CNT Fits

Our CNT triad — nicotinic acid, ascorbic acid, and L-tryptophan in precise ratio — is designed to restore metabolic homeostasis by:

• 🔋 Rebuilding NAD⁺ pools crucial for energy and repair.

• 🧠 Balancing neurotransmitter pathways to stabilize cognition and mood.

• 🛡️ Providing antioxidant/redox protection to buffer stress and aging processes.

For Cancer: CNT offers a novel nutrient-based prevention and resilience strategy by reducing redox stress, improving DNA repair, and supporting recovery post-treatment. This aligns directly with the Cancer Innovation Fund’s new emphasis on nutrition protocols.

For Alzheimer’s & Cognitive Decline: CNT functions like a scientifically grounded “multi-nutrient therapy,” targeting NAD⁺ deficits and oxidative stress that underlie aging and neurodegeneration. This is squarely in line with the Alzheimer’s program’s focus on multi-vitamin and metabolic support interventions.

What’s Next

• We will be submitting a Letter of Intent for the Cancer Innovation Fund in the coming weeks.

• Once the new Alzheimer’s FOA posts, we’ll be ready to apply there as well.

• Both opportunities put HOM3OSTASIS on the map as a Florida-based leader in nutritional therapeutics for aging, cancer, and cognition.

I couldn’t be more excited about this moment — it’s a chance to validate and expand CNT on a major stage, with direct state support. Thank you all for being part of this journey.

With gratitude and momentum,
Dmitry Kats, PhD, MPH
Founder, HOM3OSTASIS